ORCHESTRA BIOMED HOLDINGS IN (OBIO)

US68572M1062 - Common Stock

7.93  +0.04 (+0.51%)

After market: 7.93 0 (0%)

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (9/27/2023, 7:00:02 PM)

After market: 7.93 0 (0%)

7.93

+0.04 (+0.51%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)N/A N/A
Ins Owners5.53%
Inst Owners30.17%
Market Cap283.45M
Shares35.74M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.22
IPO08-04 2020-08-04
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

OBIO Daily chart

Company Profile

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The Company’s flagship product candidates are Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of artery disease, the leading cause of mortality worldwide, and BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension, a significant risk factor for death worldwide. Virtue SAB is a drug/device combination product candidate for the treatment of artery disease designed to deliver an extended-release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant. BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.

Company Info

ORCHESTRA BIOMED HOLDINGS IN

150 Union Square Drive

New Hope PENNSYLVANIA

P: 16463439298.0

Employees: 0

OBIO News

News Image8 days ago - ChartmillIn today's session, these stocks are experiencing unusual volume.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

News Image8 days ago - The Motley FoolWhy Shares of Orchestra BioMed Jumped Tuesday

The company got approval from the FDA to go ahead with a pivotal study for a hypertension therapy.

News Image9 days ago - Orchestra BioMed Holdings, Inc.Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
News Image9 days ago - Orchestra BioMed Holdings, Inc.Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually...

News Image2 months ago - Orchestra BioMed Holdings, Inc.Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
News Image2 months ago - Orchestra BioMed Holdings, Inc.Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent...

OBIO Twits

Here you can normally see the latest stock twits on OBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example